RxDoctor Payments Data

Ohan Karatoprak, MD

Family Medicine · Fort Lee, NJNPI 1588757058

Payments from drug & device makers

$230in general payments, 2019–2025

Across 7 payments — averaging $32.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$145
  • Boehringer Ingelheim$45
  • Hikma Pharmaceuticals USA$21
  • Lilly USA, LLC$19

What the payments were for

  • Food & beverage$16471%
  • Education$6629%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$230 in reported general payments places this provider in the 35th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$347,481
Medicare patients
411
Services billed
5,506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin163$154,084
EliquisApixaban125$110,252
MounjaroTirzepatide40$45,701
OzempicSemaglutide17$22,900
FarxigaDapagliflozin Propanediol32$22,802
TrulicityDulaglutide21$21,465
EntrestoSacubitril/Valsartan14$9,280
VascepaIcosapent Ethyl27$6,653
Metoprolol Succinate399$6,537
Atorvastatin Calcium421$4,313
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,595
Diclofenac Sodium95$3,363
Spironolactone-HctzSpironolact/Hydrochlorothiazid90$2,924
Losartan Potassium276$2,686
Amlodipine Besylate330$2,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$45$154,084163 claims
Lilly USA, LLCMounjaro, Trulicity$19$67,16761 claims
AbbVieSynthroid$145$98412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Fort Lee

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →